Research Article: Serum exocrine pancreas enzymes are biomarkers of immunotherapy response in new-onset type 1 diabetes
Abstract:
Introduction: The immune-mediated destruction of insulin-producing ?-cells characterizes type 1 diabetes. Nevertheless, exocrine pancreatic enzymes, including amylase, lipase, and trypsin, are also significantly reduced in type 1 diabetes. With an immunotherapy now approved to treat early-stage type 1 diabetes, biomarkers to delineate response to treatment are needed. No study has yet evaluated whether serum exocrine pancreatic enzymes could delineate immunotherapy responders and non-responders.
No summary available.